Correlation of the steady-state minimal concentration with AUC<sub>24</sub>/MIC of vancomycin and analysis of risk factors for treatment failure in pediatric patients

LIN Jinxiang; WANG Youhong; XIAO Zhifeng; WANG Jing; SONG Ying; CAI Ningfang; WU Xiuping

doi:10.6039/j.issn.1001-0408.2025.09.13

您当前的位置：

首页 >

文章列表页 >

Correlation of the steady-state minimal concentration with AUC₂₄/MIC of vancomycin and analysis of risk factors for treatment failure in pediatric patients

更新时间：2025-05-09

- Correlation of the steady-state minimal concentration with AUC₂₄/MIC of vancomycin and analysis of risk factors for treatment failure in pediatric patients
- ZHONGGUO YAOFANG Vol. 36, Issue 9, Pages: 1093-1098(2025)
- 作者机构：
  
  厦门市儿童医院/复旦大学附属儿科医院厦门医院药学部，福建厦门　361006
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.09.13
  CLC： R969
- Received：06 November 2024，
  
  Revised：31 March 2025，
  
  Accepted：2025-04-01，
  
  Published：15 May 2025
- 稿件说明：
移动端阅览
林金香,王幼鸿,肖智锋等.儿童患者万古霉素稳态血药浓度谷值与AUC₂₄/MIC的相关性及治疗失败的危险因素分析 ^Δ[J].中国药房,2025,36(09):1093-1098.

LIN Jinxiang,WANG Youhong,XIAO Zhifeng,et al.Correlation of the steady-state minimal concentration with AUC₂₄/MIC of vancomycin and analysis of risk factors for treatment failure in pediatric patients[J].ZHONGGUO YAOFANG,2025,36(09):1093-1098.
林金香,王幼鸿,肖智锋等.儿童患者万古霉素稳态血药浓度谷值与AUC₂₄/MIC的相关性及治疗失败的危险因素分析 ^Δ[J].中国药房,2025,36(09):1093-1098. DOI： 10.6039/j.issn.1001-0408.2025.09.13.

LIN Jinxiang,WANG Youhong,XIAO Zhifeng,et al.Correlation of the steady-state minimal concentration with AUC₂₄/MIC of vancomycin and analysis of risk factors for treatment failure in pediatric patients[J].ZHONGGUO YAOFANG,2025,36(09):1093-1098. DOI： 10.6039/j.issn.1001-0408.2025.09.13.

摘要

目的

评估儿童患者万古霉素稳态血药浓度谷值（

min

）与24 h药时曲线下面积（AUC

）/最小抑菌浓度（MIC）比值（AUC

/MIC）的相关性，并分析万古霉素治疗失败的独立危险因素。

方法

回顾性收集2021年1月至2024年7月于我院使用万古霉素治疗且进行治疗药物监测的住院患儿资料，按治疗是否成功分为成功组和失败组。采用Spearman相关性分析评估万古霉素

min

与AUC

/MIC的相关性，采用单因素及多因素Logistic回归分析筛选万古霉素治疗失败的独立危险因素

。

结果

共纳入59例患儿，成功组41例、失败组18例。与失败组比较，成功组患儿的万古霉素AUC

/MIC显著升高（

＝0.038）；但两组患儿的

min

比较，差异无统计学意义（

＞0.05）。万古霉素的

min

与AUC

/MIC呈显著正相关（

＝0.499，

＜0.001），但其对AUC

/MIC达标（≥400）有一定的预测效能（受试者操作特征曲线下面积＝0.696），Youden指数确定的最佳截断值为6.05 mg/L。AUC

/MIC预测治疗失败的效能优于

min

（受试者操作特征曲线下面积为0.671 vs. 0.523，

为0.038 vs. 0.684），敏感性更高（83.3% vs. 66.7%）。低蛋白血症和AUC

/MIC≤369.1是导致万古霉素治疗失败的独立危险因素（

＜0.05）。患儿肾毒性发生率为3.4%。

结论

儿童患者万古霉素的

min

与AUC

/MIC呈显著正相关；低蛋白血症和AUC

/MIC≤369.1是导致患儿万古霉素治疗失败的独立危险因素。

Abstract

OBJECTIVE

To assess the correlation between the steady-state minimal concentration （

min

） and 24 h area under the drug concentration-time curve （AUC

）/minimal inhibitory concentration （MIC） ratio （AUC

/MIC） of vancomycin in pediatric patients， and analyze independent risk factors for treatment failure.

METHODS

Data of hospitalized children treated with vancomycin and receiving therapeutic drug monitoring in our hospital from January 2021 to July 2024 were retrospectively collected and divided into success group and failure group according to whether the treatment was successful or not. Spearman correlation analysis was used to analyze the correlation between

min

and AUC

/MIC of vancomycin， and one-way and multifactorial Logistic regression analyses were used to screen the independent risk factors for vancomycin treatment failure.

RESULTS

A total of 59 children were included， with 41 in the success group and 18 in the failure group. Compared with the failure group， AUC

/MIC of vancomycin was significantly higher in the success group （

＝0.038）， but there was no statistically significant difference in the

min

of the two groups （

＞0.05）；

min

of vancomycin was significantly positively correlated with AUC

/MIC （

＝0.499，

＜0.001）， but it has a certain efficacy in predicting the achievement of the AUC

/MIC standard （≥400）（area under the receiver operator characteristic curve＝0.696）， with an optimal cutoff value of 6.05 mg/L determined by the Youden index. The efficacy of AUC

/MIC in predicting treatment failure was superior to

min

（areas under the receiver operator characteristic curve were 0.671 vs. 0.523，

were 0.038 vs. 0.684）， with higher sensitivity （83.3% vs. 66.7%）. Hypoproteinemia and AUC

/MIC≤369.1 were independent risk factors for vancomycin treatment failure （

＜0.05）. The incidence of nephrotoxicity was 3.4%.

CONCLUSIONS

There is a significant positive correlation between

min

and AUC

/MIC of vancomycin in pediatric patients； hypoproteinemia and AUC

/MIC≤369.1 are independent risk factors for vancomycin treatment failure in children.

关键词

Keywords

references

LIU C ， BAYER A ， COSGROVE S E ， et al . Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children [J ] . Clin Infect Dis ， 2011 ， 52 （ 3 ）： e18 - e55 .

CUSUMANO J A ， KLINKER K P ， HUTTNER A ， et al . Towards precision medicine：therapeutic drug monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity [J ] . Am J Health Syst Pharm ， 2020 ， 77 （ 14 ）： 1104 - 1112 .

ELYASI S ， KHALILI H . Vancomycin dosing nomograms targeting high serum trough levels in different populations：pros and cons [J ] . Eur J Clin Pharmacol ， 2016 ， 72 （ 7 ）： 777 - 788 .

LIANG X Y ， FAN Y X ， YANG M J ， et al . A prospective multicenter clinical observational study on vancomycin efficiency and safety with therapeutic drug monitoring [J ] . Clin Infect Dis ， 2018 ， 67 （ Suppl.2 ）： S249 - S255 .

LEE B V ， FONG G ， BOLARIS M ， et al . Cost-benefit analysis comparing trough，two-level AUC，and Bayesian AUC dosing for vancomycin’：authors’ reply [J ] . Clin Microbiol Infect ， 2021 ， 27 （ 6 ）： 929 - 930 .

ALNEZARY F S ， ALMUTAIRI M S ， GONZALES-LUNA A J ， et al . The significance of Bayesian pharmacokinetics in dosing for critically ill patients：a primer for clinicians using vancomycin as an example [J ] . Antibiotics （Basel）， 2023 ， 12 （ 9 ）： 1441 .

RYBAK M J ， LE J ， LODISE T P ， et al . Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections：a revised consensus guideline and review by the American Society of Health-system Pharmacists，the Infectious Diseases Society of America，the Pediatric Infectious Diseases Society，and the Society of Infectious Diseases Pharmacists [J ] . Am J Health Syst Pharm ， 2020 ， 77 （ 11 ）： 835 - 864 .

STEWART J J ， JORGENSEN S C ， DRESSER L ， et al . A Canadian perspective on the revised 2020 ASHP-IDSA-PIDS-SIDP guidelines for vancomycin AUC-based therapeutic drug monitoring for serious MRSA infections [J ] . J Assoc Med Microbiol Infect Dis Can ， 2021 ， 6 （ 1 ）： 3 - 9 .

HE N ， SU S ， YE Z K ， et al . Evidence-based guideline for therapeutic drug monitoring of vancomycin：2020 update by the Division of Therapeutic Drug Monitoring，Chinese Pharmacological Society [J ] . Clin Infect Dis ， 2020 ， 71 （ Suppl. 4 ）： S363 - S371 .

何娜，苏珊，翟所迪，等 . 《中国万古霉素治疗药物监测指南（2020更新版）》解读 [J ] . 临床药物治疗杂志， 2021 ， 19 （ 1 ）： 12 - 16 .

JORGENSEN S C J ， DERSCH-MILLS D ， TIMBERLAKE K ， et al . AUCs and 123s：a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics [J ] . J Antimicrob Chemother ， 2021 ， 76 （ 9 ）： 2237 - 2251 .

SCHWARTZ G J ， MUÑOZ A ， SCHNEIDER M F ， et al . New equations to estimate GFR in children with CKD [J ] . J Am Soc Nephrol ， 2009 ， 20 （ 3 ）： 629 - 637 .

AVEDISSIAN S N ， BRADLEY E ， ZHANG D A ， et al . Augmented renal clearance using population-based pharmacokinetic modeling in critically ill pediatric patients [J ] . Pediatr Crit Care Med ， 2017 ， 18 （ 9 ）： e388 - e394 .

高玉成，焦正，黄虹，等 . 万古霉素个体化给药决策支持系统的研制 [J ] . 药学学报， 2018 ， 53 （ 1 ）： 104 - 110 .

FRYMOYER A ， HERSH A L ， CORALIC Z ， et al . Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections：a Monte Carlo simulation [J ] . Clin Ther ， 2010 ， 32 （ 3 ）： 534 - 542 .

《抗菌药物临床试验技术指导原则》写作组 . 抗菌药物临床试验技术指导原则 [J ] . 中国临床药理学杂志， 2014 ， 30 （ 9 ）： 844 - 856 .

KHWAJA A . KDIGO clinical practice guidelines for acute kidney injury [J ] . Nephron Clin Pract ， 2012 ， 120 （ 4 ）： c179 - c184 .

ALJUTAYLI A ， EL-HAFFAF I ， MARSOT A ， et al . An update on population pharmacokinetic analyses of vancomycin，part Ⅱ：in pediatric patients [J ] . Clin Pharmacokinet ， 2022 ， 61 （ 1 ）： 47 - 70 .

郑香宜，吴建华，吴东方 . 万古霉素血药浓度低于目标治疗浓度因素分析及给药方案优化 [J ] . 中国药师， 2022 ， 25 （ 8 ）： 1442 - 1447 .

CERENZIO J ， TRUONG J . Efficacy and safety of vancomycin Bayesian-estimated area under the curve versus trough-based dosing [J ] . Ann Pharmacother ， 2023 ， 57 （ 8 ）： 931 - 939 .

NEELY M N ， YOUN G ， JONES B ， et al . Are vancomycin trough concentrations adequate for optimal dosing [J ] . Antimicrob Agents Chemother ， 2014 ， 58 （ 1 ）： 309 - 316 .

MATSUMOTO K ， ODA K ， SHOJI K ， et al . Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing：a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring [J ] . Pharmaceutics ， 2022 ， 14 （ 3 ）： 489 .

CHEN Y W ， WU D ， DONG M ， et al . Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants [J ] . Eur J Clin Pharmacol ， 2018 ， 74 （ 7 ）： 921 - 930 .

KISHK O A ， LARDIERI A B ， HEIL E L ， et al . Vancomycin AUC/MIC and corresponding troughs in a pediatric population [J ] . J Pediatr Pharmacol Ther ， 2017 ， 22 （ 1 ）： 41 - 47 .

TKACHUK S ， COLLINS K ， ENSOM M H H . The relationship between vancomycin trough concentrations and AUC/MIC ratios in pediatric patients：a qualitative syste- matic review [J ] . Paediatr Drugs ， 2018 ， 20 （ 2 ）： 153 - 164 .

DE COCK P A J G ， DESMET S ， DE JAEGER A ， et al . Impact of vancomycin protein binding on target attainment in critically ill children：back to the drawing board [J ] . J Antimicrob Chemother ， 2017 ， 72 （ 3 ）： 801 - 804 .

葛洁，丁一，关月，等 . 低蛋白血症对儿童万古霉素血药浓度监测的影响分析 [J ] . 中国医院药学杂志， 2020 ， 40 （ 12 ）： 1360 - 1363 .

张烁，熊辉 . 最低抑菌浓度漂移现象研究现状 [J ] . 中华急诊医学杂志， 2019 ， 28 （ 11 ）： 1458 - 1462 .

CONSTANCE J E ， BALCH A H ， STOCKMANN C ， et al . A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates [J ] . Arch Dis Child Fetal Neonatal Ed ， 2016 ， 101 （ 3 ）： F236 - F243 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Construction of risk prediction model for non-compliance with inhalation medication in COPD patients

Analysis of the occurrence time and risk factors of anemia in AIDS patients caused by HAART regimen containing zidovudine

Analysis of risk factors for hypokalemia caused by amphotericin B liposome

Risk factors of substandard drug blood concentration of meropenem in patients with hospital-acquired pneumonia

临床药师参与1 例神经内科ICU重症脑出血患者肺部感染的治疗分析

Related Author

WANG Na

YANG Wenming

HU Ailing

ZHAO Yanmin

YU Xiaojie

QIN Xiangsong

YAN Haiyan

HE Wenming

Related Institution

Dept. of Pharmacy， the First Hospital of Qinhuangdao

Graduate School of Youjiang Medical College for Nationalities

Dept. of Infectious Diseases， Liuzhou Municipal People’s Hospital

Liuzhou Key Laboratory of Infectious Disease Immunity Research

Guangxi Key Laboratory of Clinical Disease Biotechnology Research

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Correlation of the steady-state minimal concentration with AUC24/MIC of vancomycin and analysis of risk factors for treatment failure in pediatric patients

DOI：10.6039/j.issn.1001-0408.2025.09.13

摘要

Abstract

关键词

Keywords

references

Correlation of the steady-state minimal concentration with AUC₂₄/MIC of vancomycin and analysis of risk factors for treatment failure in pediatric patients